title: Green tea and cancer chemoprevention.
abstract: Worldwide interest in green tea as a cancer preventive agent for humans has increased, because it is non-toxic and it is effective in a wide range of organs. (-)-Epigallocatechin gallate (EGCG) is the main constituent of green tea; the others are (-)-epicatechin gallate, (-)-epigallocatechin and (-)-epicatechin (EC). This paper reports the results of our latest pharmacological and biochemical studies with 3H-EGCG, along with studies on human subjects. The study on bioavailability of 3H-EGCG in mice revealed the wide distribution of radioactivity in multiple organs. Specifically, radioactivity was found in all reported target organs of EGCG and green tea extract (digestive tract, liver, lung, pancreas, mammary gland and skin) as well as other organs (brain, kidney, uterus and ovary or testes) in mice. Recently, we demonstrated that EC enhanced incorporation of 3H-EGCG into human lung cancer cell line PC-9 cells. EC along with another cancer preventive agent sulindac also synergistically enhanced apoptosis in PC-9 cells induced by EGCG. Moreover, a case-control study on breast cancer patients revealed that high daily consumption of green tea was associated with a lower recurrence rate among Stages I and II patients. All the results suggest that consumption of green tea is a practical and effective cancer preventive both before cancer onset and after cancer treatment.
authors.affiliation: Saitama Cancer Center Research Institute, Ina, Kitaadachi-gun, Saitama 362-0806, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Suganuma
authors.forename: S
authors.initials: S
authors.lastname: Okabe
authors.forename: N
authors.initials: N
authors.lastname: Sueoka
authors.forename: E
authors.initials: E
authors.lastname: Sueoka
authors.forename: S
authors.initials: S
authors.lastname: Matsuyama
authors.forename: K
authors.initials: K
authors.lastname: Imai
authors.forename: K
authors.initials: K
authors.lastname: Nakachi
authors.forename: H
authors.initials: H
authors.lastname: Fujiki
mesh_terms: D016475:3T3 Cells; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001682:Biological Availability; D001943:Breast Neoplasms / Q000178:diet therapy; D016022:Case-Control Studies; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000517:prevention & control*; D013467:Sulindac / Q000008:administration & dosage; D013662:Tea; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D013662:Tea; D014409:Tumor Necrosis Factor-alpha; D013467:Sulindac; D002392:Catechin; C045651:epigallocatechin gallate